Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives
- PMID: 15034787
- PMCID: PMC12161861
- DOI: 10.1007/s00432-003-0530-y
Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives
Abstract
Hepatocellular carcinoma (HCC) is a typical hypervascular tumor. Many angiogenic factors have been studied in HCC, and several anti-angiogenic therapies have been tested in animal models and patients. This paper summarizes the latest findings, especially regarding the clinical significance of endothelial cell markers and angiogenic factors in HCC, and experimental and clinical anti-angiogenesis therapies. Further developments in this area, such as endothelial cell-oriented research and better experimental and clinical designs in the evaluation of anti-angiogenic therapies are discussed.
References
-
- Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y (1994) A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 54:3407–3412 - PubMed
-
- Baur M, Walter R, Gebauer A, Tscholakoff D, Lochs H, Muhlbacher F, Turetschek K, Binder R, Hudec M, Gangl A, Ferenci P, Dittrich C (2003) Chemoembolization with cisplatin, lipiodol and Gelfoam and subsequent systemic chemotherapy with cisplatin and interferon in patients with hepatocellular carcinoma: a non-randomized prospective study. Int J Oncol 23:811–819 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
